Firefly luciferase mRNA-LNP
Based on 1 publication(s) in Google Scholar
Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency.
For research use only. We do not sell to patients.
-
Storage:
-80°C
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Firefly luciferase mRNA-LNP
More
Customer Validation & Images
-
In Vivo Imaging
Biological Activity
Firefly luciferase mRNA-LNP (5-20 ng, 24 h) significantly increases the transfection efficiency dose-dependently in HepG2 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Firefly luciferase mRNA-LNP (1 μg, i.m., on day 1 and day 21) is formulated with either ALC-0315 or SM-102, and SM-102 has 60% higher expression level of luciferase protein than ALC-0315 and cKK-E12 in BALB/c mice[4].
Firefly luciferase mRNA-LNP (5-20 μg, i.m., single dose) induces activation of Aif1 in the hypothalamus but not in the prefrontal cortex of adult Balb/c male mice[5].
Firefly luciferase mRNA-LNP (5 μg, i.m./i.v./i.p./i.t., single dose) results in a large portion of the luciferase activity as well as high levels of protein production in the liver, and significant bioluminescent signal in lungs and muscles of BALB/c mouse model[6].
Firefly luciferase mRNA-LNP (5 μg, i.d./s.c., single dose) results in protein production only at the site of injection in BALB/c mouse model[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c mice aged 6 weeks[1]
-
Dosage:0.1, 1.0, 5.0 μg
-
Administration:Intradermal injection (i.d.)/Intraperitoneal injection (i.p.)/Subcutaneous injection (s.c.)/Intramuscular injection (i.m.)/Intravenous injection (i.v.)/Intratracheal injection (i.t.)
-
Result:Could not measure signal when mice were injected with 0.1 μg of mRNA-LNPs.
Resulted in the highest amount of peak protein production and the shortest duration of expression with intravenous delivery.
Did not result in measurable luciferase expression in the liver or other anatomical sites with subcutaneous delivery.
Resulted in the longest duration of translation with intramuscular and intradermal delivery.
Allowed saturation of the uptake or translational capacity of the intradermal space with intradermal delivery.
Observed linear dose response with intravenous injection.
Led to similar levels of peak translation at 4 h post injection with all three doses, but the increased doses extended the duration of translation from 5 (1.0 μg) to 10 (5.0 μg) days.
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Firefly luciferase mRNA-LNP]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
Macrophage-targeted Mms6 mRNA-lipid nanoparticles promote locomotor functional recovery after traumatic spinal cord injury in mice. [Abstract]2025 Mar 28;11(13):eads2295. PMID: 40138430
Firefly luciferase mRNA-LNP purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Mar 28;11(13):eads2295. [Abstract]
Representative in vivo imaging system images of major organs in SCI mice after being administered with firefly luciferase (FLuc) mRNA-LNPs (0.5 mg mRNA/kg). From left to right are the heart, liver, spleen, lung, two kidneys, and spinal cord. iv, intravenous; ip, intraperitoneal.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tenchov, R., et al., (2021). Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS nano, 15(11), 16982-17015. [Content Brief]
[2]. Xu YZ, et al. Promoter deletion analysis using a dual-luciferase reporter system. Methods Mol Biol. 2013;977:79-93. [Content Brief]
[3]. El-Mayta, R., et al., (2023). Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing. Journal of visualized experiments: JoVE, (191), 10.3791/64810. [Content Brief]
[4]. Zhang, L., et al., (2023). Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ vaccines, 8(1), 156. [Content Brief]
[6]. Pardi, N., et al., (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of controlled release: official journal of the Controlled Release Society, 217, 345–351. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Firefly luciferase mRNA-LNP Related Classifications
HY-153229 Related Classifications
Powered by Bioz